Leaving Practice
January 10, 2024
Dear OMIC Insureds:
Ophthalmologists leave practices for many reasons, including illness, retirement, changes in employment status, and personal or family needs. Both the individual ophthalmologist and the practice need to take steps in order to promote continuity of care, prevent allegations of abandonment, and ensure that all involved ophthalmologists have access to the medical records in the event the care is ever called into question.
The leaving practice toolkit addresses the risks posed when an ophthalmologist retires or leaves a practice.
If you have questions, contact us for confidential risk management advice at riskmanagement@omic.com or call us at 1-800-562-6642 and enter 4 for Risk Management.
Sincerely,
Michelle Pineda, MBA
OMIC Risk Management
CONFIDENTIALITY NOTICE: This correspondence is intended only for the person or entity to which it is addressed and may contain information that is privileged, confidential or otherwise protected from disclosure. Dissemination, distribution or copying of this e-mail or the information herein by anyone other than the intended recipient, or an employee or agent responsible for delivering the message to the intended recipient, is prohibited. If you have received this e-mail in error, please notify us at riskmanagement@omic.com and destroy the original message and all copies.
______________________________________
Izervay™ Sample Consent and Eylea®HD form now available
|
|||
|
|||
|
Revised ROP Conditions of Coverage and New ROP Telemedicine Protocols
|
OMIC Courses at AAO 2023
October 18, 2023
Dear OMIC Colleagues:
Please join us at the 2023 AAO Annual Meeting at Moscone Center in San Francisco, CA. We are offering OMIC courses to physicians, technicians, and administrators. Please see the attached list of courses.
You can also ask us your specific questions at OMIC Booth #7329, Moscone Center, West Hall, Level 1.
Thank you for being a member of OMIC!
Sincerely,
Linda D. Harrison, PhD
Vice President, OMIC Risk Management
Pine Pharmaceuticals Announces Voluntary Recalls, Including Avastin
October 4, 2023
Dear OMIC Insureds:
According to a bulletin from the American Academy of Ophthalmology(AAO), Pine Pharmaceuticals elected to issue a voluntary recall for specific lots of repackaged bevacizumab (Avastin). OMIC recommends you review the AAO bulletin (which includes letters from the manufacturer) and consider the following, while continuing to monitor the situation:
Since there are no reports of harm to patients, there is not an immediate need to notify patients who have received prior doses of Avastin prepared by Pine Pharmaceuticals. However, if the situation changes, or if it is part of your drug recall response plan to notify patients regardless of reports of harm, you should proceed with identifying and notifying affected patients. Healthcare professionals should immediately check their medical supplies, quarantine any drugs intended to be sterile and prepared by Pine Pharmaceuticals, and not administer or provide them to patients. Since this may result in a shortage of the drug, you should consider alternative sources that adhere to proper quality standards.
If you have questions about this topic or would like to have a confidential risk management consultation, please email riskmanagement@omic.comor call the Risk Management Hotline at 1-800-562-6642 and enter 4 for Risk Management.
Sincerely,
Michelle Pineda, MBA
OMIC Risk Manager
